Navigation Links
Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors
Date:10/10/2007

PALO ALTO, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today the appointment of its C.E.O., Belinda Tsao-Nivaggioli, Ph.D., to the additional role of Chairman of the Company's Board of the Directors. Dr. Tsao- Nivaggioli succeeds Nasser Menhall, who recently resigned from the Board to focus his time on other business ventures.

"I want to take this opportunity to thank Nasser for his many contributions and his invaluable leadership over many years and I wish him best of luck in his new ventures," stated Dr. Tsao-Nivaggioli. "I appreciate the Board of Directors' vote of confidence and I continue to be proud to be associated with this organization and its people. I look forward to leading this Company and to further leveraging our cellular energy technology to develop and commercialize pharmaceutical and dermaceutical products."

Prior to her current roles of CEO and Chairman, Dr. Tsao-Nivaggioli was Avicena's chief operating officer from 2002 to 2004. During her tenure with the Company, Dr. Tsao-Nivaggioli has expanded its intellectual property portfolio and built a substantial pipeline of pharmaceutical products, including drug candidates for the treatment of neurological disorders such as ALS, Huntington's and Parkinson's Disease. Dr. Tsao-Nivaggioli is also credited with solidifying the Company's relationship with the National Institutes of Health (NIH) as well as developing the Company's dermaceutical programs.

ABOUT AVICENA

Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a Palo Alto, California based late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders. The Company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the Company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trail in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

Contact:

The Ruth Group (on behalf of Avicena Group)

Sara Ephraim (investors)

(646) 536-7002

sephraim@theruthgroup.com

Janine McCargo / Jason Rando (media)

(646) 536-7033 / 7025

jmccargo@theruthgroup.com or jrando@theruthgroup.com


'/>"/>
SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Avicena to Advance Huntingtons Disease Clinical Program into Phase III
2. Study casts doubt on keyboard ills
3. Who Board To Discuss Asian Tsunami Related Health Issues
4. Abdominal Crunches Not The Best Option For Wash Board Abs.
5. Computer Keyboards In Hospitals Could Spread Infection To Patients
6. Flu, Boarded A Ship?
7. Skateboarding to health
8. Shangai Citizens to Monitor Billboards
9. Budhia Is Fine, Government-constituted Medical Board Reports False
10. Pharmacy Board Says Pharmacists Have Right To Refuse Morning-After Pill
11. 115 people on board a cruise liner taken ill due to suspected Norovirus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ‘Tis the ... winners of $1,000 each from the National Family Partnership and the Drug Enforcement Administration ... who decorated their homes and the 10 winning schools who decorated their campuses with ...
(Date:11/30/2016)... ... ... "I hate when the mixture of saliva and toothpaste runs down my toothbrush ... N.J. "I thought that there had to be a way to prevent this mess, ... to prevent saliva and toothpaste from running down the brush handle onto the hand ...
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new residential ... treatment for girls with mental health issues such as severe anxiety, depression, bi-polar ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... community that the FDA Binding Guidance goes into effect next month. Sponsors whose ... in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices ... ... The full report suite on the ... fluid external drainage systems, intracranial pressure monitoring devices, detachable coils, ...
(Date:11/30/2016)... Nov. 30, 2016 Varian Medical Systems (NYSE: ... America,s Most JUST Company in the Healthcare Equipment and ... magazine,s inaugural "JUST 100 List." The rankings are ... surveys ever conducted on attitudes towards corporate behavior, involving ... list ranks U.S companies against their peers within 32 ...
Breaking Medicine Technology: